Adiponectin and the Incidence of Type 2 Diabetes in Hispanics and African Americans

The IRAS Family Study

Anthony J.G. Hanley, PhD1,2
Lynne E. Wagenknecht, DRPH3
Jill M. Norris, PhD4
Richard Bergman, PhD5
Andrea Anderson, MSC3
Y. Ida Chen, PhD6
Carlos Lorenzo, MD7
Steven M. Haffner, MD8

OBJECTIVE—A recent meta-analysis of 13 prospective studies reported that higher levels of adiponectin were significantly associated with lower risk of type 2 diabetes. Most previous studies, however, were limited in their ability to adjust for appropriate confounding variables. Our objective, therefore, was to study this association after adjustment for directly measured adiposity and insulin sensitivity, expressed as the insulin sensitivity index (SI).

RESEARCH DESIGN AND METHODS—The study included 1,096 Hispanic and African American participants free of diabetes at baseline (2000–2002) who returned for follow-up after 5 years. SI was determined from frequently sampled intravenous glucose tolerance tests with minimal model analysis. Visceral adipose tissue (VAT) area was determined by computed tomography. Diabetes and impaired fasting glucose (IFG) were defined using American Diabetes Association criteria. Multivariate generalized estimating equation logistic regression models were used to account for correlations within families.

RESULTS—A total of 82 subjects met criteria for incident diabetes. After adjustment for age, sex, ethnicity, and smoking, adiponectin was significantly inversely associated with diabetes (odds ratio [OR] 0.54 per 1 SD difference [95% CI 0.38–0.76]). The association remained significant after additional adjustment in individual models for BMI, homeostasis model assessment of insulin resistance, or VAT (all P < 0.05). However, adiponectin was no longer associated in separate models adjusted for SI or IFG (OR 0.81 [0.56–1.16] and 0.75 [0.53–1.06], respectively).

CONCLUSIONS—Adiponectin was inversely associated with incident diabetes after adjustment for conventional anthropometric and metabolic variables or VAT. Adjustment for detailed measures of SI attenuated this relationship, however, suggesting that the link between adiponectin and diabetes may operate at least in part through insulin resistance.

Diabetes Care 34:2231–2236, 2011

Since its discovery in the mid-1990s, the adipocyte-derived protein adiponectin has been reported to have a broad spectrum of effects, including antithrombotic, anti-inflammatory, and insulin-sensitizing properties (1,2). In addition to the established inverse associations of adiponectin with various measures of adiposity, one of the most consistent observations in this literature is the prospective association of higher baseline adiponectin levels with reduced risk of type 2 diabetes (3). A recent meta-analysis of 13 prospective studies involving 14,598 participants and 2,623 incident cases of type 2 diabetes reported a robust inverse association of adiponectin with incident type 2 diabetes across diverse populations, with a pooled relative ratio of 0.72 (95% CI 0.67–0.78) per 1-log μL/mL increase (4).

Despite these concordant findings regarding adiponectin and incident diabetes, a number of questions remain unanswered. First, the majority of previous studies have involved Asian populations or Caucasians from Europe or North America (4), with few studies involving African Americans or Hispanics, who are known to be at increased risk of diabetes (5,6). Furthermore, relatively few studies to date have adjusted for HDL cholesterol, which may be an important covariate because HDL is strongly correlated with adiponectin and low HDL is a documented diabetes risk factor (7,8). In addition, the majority of previous reports have adjusted for surrogate measures of insulin resistance and adiposity (4). This is an important limitation in light of the central role of insulin resistance and visceral fat in adiponectin pathobiology (9,10) and the modest validity of the proxy measures of these disorders that have been used to date (BMI and homeostasis model assessment of insulin resistance [HOMA-IR]). In one previous study, the association of adiponectin with incident diabetes was assessed in a cohort of elderly African Americans and whites after adjustment for directly assessed visceral adipose tissue (VAT) (11), although no previous study to our knowledge has used direct measures of both VAT and insulin sensitivity, expressed as the insulin sensitivity index (SI). Another recent study documented an association of adiponectin with incident diabetes in insulin-resistant subjects but not in those who were insulin sensitive (12).
Adiponectin and incident type 2 diabetes

The objective of the current study, therefore, was to investigate the association of adiponectin with incident type 2 diabetes after adjustment for potential confounders, including directly measured VAT and $S_i$ as well as HDL, in the Insulin Resistance Atherosclerosis Study (IRAS) Family Study, a prospective cohort study of well-characterized Hispanic and African American adults.

**RESEARCH DESIGN AND METHODS**—The methodology of the IRAS Family Study has been described in detail (13,14). Briefly, the study was designed to explore genetic contributions to insulin resistance and visceral adiposity among Hispanic and African American adults using a family-based design (13). Large families were recruited between 2000 and 2002 at centers in San Antonio, TX, San Luis Valley, CO (Hispanics), and Los Angeles, CA (African Americans), with probands identified from the parent study (IRAS) (13) as well as the general population. The present prospective analysis included 1,096 subjects who were free of diabetes at the baseline examination (2000–2002) and who returned for the 5-year follow-up examination, representing a 77% participation rate at follow-up. Subjects who did not return at follow-up were more likely to be male and have slightly better health status than those that returned (including slightly lower levels of subcutaneous adipose tissue [SAT] and VAT and higher $S_i$). The institutional review boards at the respective institutions approved the protocol, and informed consent was given by each subject.

Fat mass in the abdominal region was measured by computed tomography at both the L2/L3 and L4/L5 vertebral regions (13,14). A standardized protocol was used at each of the three clinical centers. Scans were read centrally at the University of Colorado School of Medicine, Department of Radiology, Bio-Imaging Research Laboratory for SAT and VAT, with bowel fat subtracted out from the measure of VAT. The L4/L5 measure was used in the present analysis. However, 45 subjects had data for the L2/L3 region but not the L4/L5 region. Since adipose tissue areas at the L2/L3 and L4/L5 regions were highly correlated (Spearman correlation: 0.95 for SAT, 0.90 for VAT), data for these latter individuals for the L4/L5 region were imputed using a simple linear model (13,14).

Insulin sensitivity was determined using a frequently sampled intravenous glucose tolerance test, with two modifications to the original protocol (15). First, an injection of regular insulin, rather than tolbutamide, was used to ensure adequate plasma insulin levels for the accurate computation of insulin sensitivity across a broad range of glucose tolerance (15). Second, a reduced sampling protocol (with 12 rather than 30 samples) was used for efficiency, given the large number of participants (15). $S_i$ was calculated using minimal model analysis (13–15).

Plasma glucose was measured using the glucose oxidase technique on an autoanalyzer. At both baseline and follow-up examinations, impaired fasting glucose (IFG) was defined as fasting glucose ≥100 and <126 mg/dL, and diabetes was diagnosed as either a fasting glucose ≥126 mg/dL or use of antidiabetic medications. Plasma insulin was measured using the dextran-charcoal radioimmunoassay (16), which has a 19% inter-assay coefficient of variation. Fasting indices of insulin resistance and β-cell function were calculated using the HOMA (HOMA-IR and HOMA-B) method of Matthews et al. (17). Lipids were determined using standard laboratory procedures. Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. Duplicate measures were made following a standardized protocol and averages used in the analysis. Ethnicity, smoking, and alcohol consumption were assessed by self-report.

Adiponectin concentration was measured using a radioimmunoassay (Linco Research, St. Charles, MO), with intra- and inter-assay coefficients of variation of 9.3, 6.9, and 9.3% and 3.6, 6.2, and 1.8%, respectively, at concentrations of 1.5, 3.0, and 7.5 μg/mL.

**Statistical analysis**

SAS version 9.1 (SAS Institute, Cary, NC) was used for all statistical analyses. Data are presented as percent for categorical variables and mean (SD) or median (interquartile range) for normally distributed and skewed continuous variables, respectively. Univariate comparisons of baseline variables across ethnic groups and follow-up diabetes status were calculated from generalized estimating equation (GEE1) models, adjusting for correlations within families. Pearson correlation analysis was used to evaluate the univariate associations of adiponectin with metabolic and anthropometric variables at baseline, with P values adjusted for family structure using GEE models.

GEE1 logistic regression models were used to test for associations of adiponectin with incident diabetes at the 5-year examination, while accounting for familial correlations. GEEs are a standard approach to the analysis of correlated data, such as family data, and are similar to logistic regression models except that they account for the correlation among pedigrees. Newly diagnosed diabetes at the 5-year follow-up examination was the dependent variable for all models. A multistage modeling approach was used to investigate the relationships of adiponectin, treated as a continuous variable, with risk of diabetes. Odds ratios (ORs) were estimated per SD increase in adiponectin. We first determined the associations of adiponectin with risk of diabetes adjusted for age, sex, ethnicity (previous cross-sectional analysis of this cohort documented ethnic differences in adiponectin, VAT, and insulin resistance) (10), and smoking. We then tested (using the same adjustments) for effect modification of sex, ethnicity, baseline glucose tolerance status (normal fasting glucose [NFG] vs. IFG), and insulin resistance (HOMA-IR < vs. ≥ median split) on the association of adiponectin with incident diabetes. Effect modification was assumed to be present if the P value for the interaction term was < 0.05. Finally, we assessed the impact, in separate models, of further adjustment of our initial model for HDL cholesterol, fasting glucose, and indirect and direct measures of adiposity and insulin sensitivity. Specifically, we ran additional models that adjusted for age, sex, ethnicity, and smoking as well as HDL, BMI, VAT, SAT, VAT + SAT, HOMA-IR, $S_i$, fasting glucose, and IFG.

**RESULTS**—Baseline demographic, anthropometric, and metabolic characteristics of participants according to incident diabetes status are presented in Table 1. In addition to being older at baseline, those who had developed diabetes at the 5-year follow-up examination had higher baseline BMI, VAT, and SAT and lower insulin sensitivity (all P < 0.001). In addition, converters had higher baseline fasting glucose concentrations and a higher prevalence of IFG (both P < 0.0001), although the two groups did not differ by sex or ethnicity. Baseline concentrations of adiponectin were significantly lower in converters compared with nonconverters (10.0 vs. 12.1 μg/mL, respectively, P < 0.001). At baseline, adiponectin was
significantly correlated with all anthropometric and metabolic measures (all $P < 0.001$) (Table 2), the strongest correlations being with VAT ($r = -0.31$), HDL ($r = 0.37$), fasting insulin ($r = -0.31$), $S_t$ ($r = 0.29$), and HOMA-IR ($r = -0.31$).

After adjustment for age, sex, ethnicity, and smoking, baseline adiponectin was significantly inversely associated with risk of incident diabetes (OR 0.54 [95% CI 0.38–0.76] per SD increase). There were no significant interactions of sex, ethnicity, baseline glucose tolerance status (NGT vs. IFG), or insulin resistance (median split of HOMA-IR) on the association of adiponectin with incident diabetes (all interaction $P \geq 0.28$).

Although subgroup associations were not uniformly significant because of reduced power, all ORs were <1.0, indicating a consistent pattern of inverse relationships between adiponectin and incident diabetes within each group (Fig. 1). We also analyzed $S_t$ as a potential effect modifier by examining subgroups defined by the median split of $S_t$. There were, however, very few converters to diabetes in the high $S_t$ (i.e., the most insulin sensitive) group, resulting in nonconvergence of our statistical model for that subgroup (data not shown).

Figure 2 illustrates the impact of further adjustment of our initial model for HDL, glucose, IFG, and indirect and direct measures of adiposity and insulin sensitivity in separate models. The association of adiponectin with incident diabetes remained statistically significant after adjustment for HDL as well as the indirect measures BMI and HOMA-IR (OR 0.64 [95% CI 0.43–0.94], 0.67 [0.46–0.97], and 0.69 [0.49–0.99], respectively; all $P < 0.05$). Notably, models adjusted for SAT, VAT, or both of these variables also maintained statistical significance (OR 0.68 [CI 0.47–0.97], 0.60 [0.41–0.88], and 0.68 [0.46–0.99], respectively; all $P < 0.05$). However, adjustment for directly measured insulin sensitivity, alone or in combination with VAT, attenuated the association of adiponectin with incident diabetes to nonsignificance (OR 0.81 [0.56–1.16] and 0.85 [0.59–1.24]; both $P > 0.05$). Finally, adjustment for fasting glucose or IFG also attenuated the adiponectin–incident diabetes association to nonsignificance (OR 0.83 [0.58–1.19] and 0.75 [0.53–1.06]; both $P > 0.05$).

**CONCLUSIONS**—In this cohort of Hispanics and African Americans, adiponectin significantly inversely predicted incident type 2 diabetes after adjustment for demographic variables as well as surrogate measures of body mass and insulin resistance. There were no significant interactions by sex, ethnicity, glucose tolerance, or insulin resistance on this association. Adjustment for VAT or SAT (or both) attenuated the association somewhat, but it remained statistically significant. This inverse association was apparent when models were adjusted for directly measured insulin sensitivity, IFG, or fasting glucose, although the ORs were no longer statistically significant.

These findings contribute novel information to the literature on adiponectin and risk of diabetes. Specifically, this article reports that adiponectin predicts incident diabetes in two ethnic groups for which relatively limited data are available.
Adiponectin and incident type 2 diabetes

Figure 1—Associations of baseline adiponectin with incident diabetes at the 5-year follow-up examination, overall, and stratified by sex, ethnicity, glucose tolerance status (NFG vs. IFG), and insulin resistance in the IRAS Family Study. ORs (95% CI) are from GEE1 logistic regression, refer to 1 SD changes in adiponectin concentration, and are adjusted for age, sex, ethnicity, and smoking status. Note log scale of x-axis.

Figure 2—Association of adiponectin with incident diabetes: impact of adjustment for glucose, HDL, and direct and surrogate measures of adiposity and insulin sensitivity. ORs are from GEE1 logistic regression and refer to risk associated with an SD increase in adiponectin, with adjustment for the indicated variables in separate models.
in the present analysis may be related to variation in adiponectin and may help to explain its independence as a diabetes predictor (10,21,22). To our knowledge, only one previous study has used information on VAT as a covariate in modeling the adiponectin–diabetes relationship. In the Health Aging and Body Composition study, a cohort study of older black and white participants, adiponectin was not significantly related to diabetes incidence in a multivariate model that included VAT in addition to conventional cardiometabolic variables, leptin, and PAI-1 (11). Given the inclusion of additional covariates (especially the leptin and PAI-1), it is not possible to isolate the impact of adjustment for VAT from this model.

In addition to adiposity, insulin resistance is another key covariate in the adiponectin–diabetes relationship, considering that the insulin-sensitizing effects of adiponectin have been demonstrated previously (3). A limited number of prior studies have adjusted for surrogate measures of insulin resistance, usually by using fasting insulin or indices derived from this variable, and in most cases, but not all, the association of adiponectin with incident diabetes remained statistically significant (4). The results of the current study are consistent with these findings because the association of adiponectin with diabetes development remained significant after adjustment for HOMA-IR. However, the association was attenuated and became nonsignificant after adjustment for directly measured insulin sensitivity. This observation suggests that a primary antidiabetic aspect of adiponectin may be its effect on increasing insulin sensitivity. Previous cross-sectional analysis in this cohort has shown that adiponectin and insulin sensitivity are independently associated (10), and it has been demonstrated in other studies that low plasma adiponectin concentrations at baseline precede declines in insulin sensitivity over time (23–25). In contrast to a recent study by Hivert et al. (12), the association of adiponectin with incident diabetes was not modified by insulin resistance, an inconsistency which may be the result of marked ethnic and metabolic differences between the participants in the two studies. Additional research is needed on the potential modifying effect of insulin resistance on adiponectin’s role in diabetes pathogenesis.

Finally, the association of adiponectin with diabetes onset was evaluated after HDL adjustment, given that relatively few previous studies had considered this covariate. This question was of interest since strong associations between HDL and adiponectin had previously been documented (7), including a strong loading of HDL and adiponectin together in a factor analysis of metabolic syndrome variables and a prospective association of baseline adiponectin with increases in HDL (23). However, our finding of a significant association of adiponectin with incident diabetes after HDL adjustment suggests that these two variables may be linked through mechanisms that are not directly related to diabetes pathogenesis.

The strengths of this study include the availability of direct measures of insulin sensitivity and body composition in a well-characterized prospective cohort of Hispanics and African Americans, two ethnic groups that are known to be at increased risk of diabetes and for whom little is known regarding the prospective association of adiponectin with diabetes. Limitations include the lack of oral glucose tolerance tests, which possibly resulted in the misclassification of subjects who would have been diagnosed as having diabetes based on elevated postchallenge glucose levels. In addition, the period of follow-up was relatively short and there were relatively few incident cases of diabetes, resulting in limited power to detect statistical interactions and/or associations with diabetes in fully adjusted models. In light of ethnic differences in adiponectin levels, future studies with sufficient power to examine ethnic-specific effects are needed. Finally, the assay used for determination of adiponectin concentrations measured “total” adiponectin and, thus, was not able to differentiate the different isoforms of the protein, the distributions of which have been shown to differ by ethnicity. It has been demonstrated that the high molecular weight isoform of adiponectin is responsible for its insulin-sensitizing effects (3).

In conclusion, adiponectin significantly predicts the 5-year incidence of type 2 diabetes after adjustment for covariates including demographic variables, HDL, surrogate measures of body mass and insulin resistance, and direct measures of visceral and subcutaneous fat. However, adjustment for directly measured insulin sensitivity, IFG, or fasting glucose attenuated this association to nonsignificance. These observations suggest that while derived from adipose tissue, adiponectin exerts its antidiabetic effect in part independently of the visceral and subcutaneous fat mass. The attenuating effect of a precise measure of insulin sensitivity on this relationship may indicate that the antidiabetic effect of adiponectin is derived primarily through the amelioration of insulin resistance.

Acknowledgments—The IRAS Family Study is supported by National Institutes of Health grants HL-60944-02, HL-61210-02, HL-61019-02, HL-60894, and HL-60931-02. A.J.G.H. holds a Canada Research Chair in Diabetes Epidemiology.

No potential conflicts of interest relevant to this article were reported.

A.J.G.H. wrote the manuscript. L.E.W., J.M.N., and R.B. researched data, contributed to discussion, and reviewed and edited the manuscript. A.A. conducted the statistical analysis and reviewed and edited the manuscript. Y.I.C., C.L., and S.M.H. researched data, contributed to discussion, and reviewed and edited the manuscript.

References

1. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167–175.

2. Goldstein BJ, Scala R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563–2568.

3. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(Suppl. 1):S64–S73.

4. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–188.

5. Hall WD, Clark LT, Wenger NK, et al.; African-American Lipid and Cardiovascular Council. The Metabolic Syndrome in African Americans: a review. Ethn Dis 2003;13:414–428.

6. Caballero AE. Diabetes in the Hispanic or Latino population: genes, environment, culture, and more. Curr Diab Rep 2005;5:217–225.

7. Côté M, Maurière P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005;90:1434–1439.

8. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010;59:1153–1160.

9. Cnop M, Havel PJ, Utschneider KM, et al. Relationship of adiponectin to body fat...
Adiponectin and incident type 2 diabetes

distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46: 459–469

10. Hanley AJ, Bowden D, Wagenknecht LE, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92:2665–2671

11. Kanaya AM, Harris T, Goodpaster BH, Tylavsky F, Cummings SR; Health, Aging, and Body Composition (ABC) Study. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 2004;27:1375–1380

12. Hivert MF, Sullivan LM, Shrader P, et al. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetes Care 2011;34:1019–1024

13. Henkin L, Bergman RN, Bowden DW, et al. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol 2003;13:211–217

14. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003;52: 2490–2496

15. Steil GM, Volund A, Kahn SE, Bergman RN. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 1993;42:250–256

16. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965;25: 1375–1384

17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412–419

18. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002, 87:5662–5667

19. Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 2002; 34:622–628

20. Jain SH, Massaro JM, Hoffmann U, et al. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study. Diabetes Care 2009;32:903–908

21. Williams CJ, Fargnoli JL, Hwang JJ, et al. Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care 2008;31:504–507

22. Metcalf BS, Jeffery AN, Hosking J, Voss LD, Sattar N, Wilkin TJ. Objectively measured physical activity and its association with adiponectin and other novel metabolic markers: a longitudinal study in children (EarlyBird 38). Diabetes Care 2009;32:468–473

23. Hanley AJ, Connelly PW, Harris SB, Zinman B. Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 2003;26:3219–3225

24. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51: 1884–1888

25. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia. Diabetologia 2010;53:268–276